See more : View United Real Estate Development Co. (9591.SR) Income Statement Analysis – Financial Results
Complete financial analysis of Frequency Therapeutics, Inc. (FREQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Frequency Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- GRM Overseas Limited (GRMOVER.NS) Income Statement Analysis – Financial Results
- Sineng Electric Co.,Ltd. (300827.SZ) Income Statement Analysis – Financial Results
- IGO Limited (IGO.AX) Income Statement Analysis – Financial Results
- centrotherm international AG (CTNK.F) Income Statement Analysis – Financial Results
- Bon Natural Life Limited (BON) Income Statement Analysis – Financial Results
Frequency Therapeutics, Inc. (FREQ)
About Frequency Therapeutics, Inc.
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 14.07M | 36.98M | 28.95M | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 14.07M | 36.98M | 28.95M | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 49.42M | 60.92M | 37.42M | 18.78M | 11.88M | 11.97M |
| General & Administrative | 33.58M | 37.18M | 27.12M | 30.84M | 7.06M | 4.34M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 33.58M | 37.18M | 27.12M | 30.84M | 7.06M | 4.34M |
| Other Expenses | 1.06M | -266.00K | 0.00 | 16.00M | 0.00 | 0.00 |
| Operating Expenses | 83.00M | 98.10M | 64.53M | 49.62M | 18.94M | 16.31M |
| Cost & Expenses | 83.00M | 98.10M | 64.53M | 49.62M | 18.94M | 16.31M |
| Interest Income | 1.33M | 397.00K | 994.00K | 1.78M | 0.00 | -174.00K |
| Interest Expense | 961.00K | 764.00K | 0.00 | 1.78M | 106.00K | 174.00K |
| Depreciation & Amortization | 2.38M | 2.91M | -80.00K | -145.00K | 654.00K | 531.00K |
| EBITDA | -80.62M | -81.13M | -27.55M | -20.68M | -18.29M | -12.02M |
| EBITDA Ratio | 0.00% | -576.66% | -74.71% | -71.92% | 0.00% | 0.00% |
| Operating Income | -83.00M | -84.03M | -27.55M | -20.68M | -18.94M | -16.31M |
| Operating Income Ratio | 0.00% | -597.32% | -74.49% | -71.42% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.42M | -640.00K | 1.07M | 1.93M | -224.00K | -3.93M |
| Income Before Tax | -81.58M | -84.67M | -26.48M | -18.75M | -19.17M | -20.24M |
| Income Before Tax Ratio | 0.00% | -601.87% | -71.59% | -64.76% | 0.00% | 0.00% |
| Income Tax Expense | -2.00K | 15.00K | 35.00K | -2.74M | -118.00K | 3.93M |
| Net Income | -81.58M | -84.69M | -26.51M | -16.00M | -19.17M | -20.24M |
| Net Income Ratio | 0.00% | -601.98% | -71.68% | -55.29% | 0.00% | 0.00% |
| EPS | -2.33 | -2.47 | -0.82 | -1.85 | -1.59 | -1.68 |
| EPS Diluted | -2.33 | -2.47 | -0.82 | -1.85 | -1.59 | -1.68 |
| Weighted Avg Shares Out | 35.08M | 34.35M | 32.25M | 8.65M | 12.06M | 12.06M |
| Weighted Avg Shares Out (Dil) | 35.08M | 34.35M | 32.25M | 8.65M | 12.06M | 12.06M |
Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences
Frequency Therapeutics' Hearing Loss Candidate Shows Improved Speech Perception In Noise
Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise
Frequency Therapeutics, Inc. (FREQ) Reports Q3 Loss, Lags Revenue Estimates
Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results
Frequency Therapeutics redesigns study after disappointing Phase 2 results, debuts new hearing loss and MS drugs
Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis
Analysts Estimate Frequency Therapeutics, Inc. (FREQ) to Report a Decline in Earnings: What to Look Out for
Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program
Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint
Source: https://incomestatements.info
Category: Stock Reports